PharmVar GeneFocus: CYP2A6.

Journal: Clinical pharmacology and therapeutics

Volume: 

Issue: 

Year of Publication: 

Affiliated Institutions:  Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada. Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. PharmGenetix GmbH, Niederalm, Austria. Department of Biomedical Data Science, Stanford University, Stanford, California, USA. Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.

Abstract summary 

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the human CYP2A gene locus containing the highly polymorphic CYP2A6 gene. CYP2A6 plays a role in the metabolism of nicotine and various drugs. Thus, genetic variation can substantially contribute to the function of this enzyme and associated efficacy and safety. This GeneFocus provides an overview of the clinical significance of CYP2A6, including its genetic variation and function. We also highlight and discuss caveats in the identification and characterization of allelic variation of this complex pharmacogene, a prerequisite for accurate genotype determination and prediction of phenotype status.

Authors & Co-authors:  Langlois Alec W R AWR Chenoweth Meghan J MJ Twesigomwe David D Scantamburlo Giada G Whirl-Carrillo Michelle M Sangkuhl Katrin K Klein Teri E TE Nofziger Charity C Tyndale Rachel F RF Gaedigk Andrea A

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Hukkanen, J., Jacob, P. & Benowitz, N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57, 79–115 (2005).
Authors :  10
Identifiers
Doi : 10.1002/cpt.3387
SSN : 1532-6535
Study Population
Male,Female
Mesh Terms
Other Terms
Study Design
Study Approach
Country of Study
Publication Country
United States